EXP012
/ Excalipoint Therapeutics, Lepu Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
A next-generation tri-specific T cell engager targeting CDH17 with 4-1BB co-stimulation for the treatment of gastrointestinal cancers
(AACR 2026)
- "CDH17-CD3-4-1BB tri-specific TCE represents a novel CDH17-targeted T cell engager with potent and durable anti-tumor activity. Collectively, these results underscore its potential as a novel therapeutic agent against GI cancers and support its advancement into clinical development."
Trispecific • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CDH17 • IL6
1 to 1
Of
1
Go to page
1